DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation Potential to be the first FDA-approved therapeutic...
Commitment
Published 09-05-24Submitted by Science Applications International Corporation (SAIC)SAIC LogoSAIC has a long history of delivering innovative solutions to our customers,...
